Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis-Reference-Cited by-同舟云学术

Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis

Published:2021-10-29 Issue:1 Volume:40 Page:12-22
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Ceriani Luca¹²^ORCID,Milan Lisa¹,Cascione Luciano²³,Gritti Giuseppe⁴,Dalmasso Federico⁵,Esposito Fabiana⁶,Pirosa Maria Cristina⁶,Schär Sämi⁷,Bruno Andrea⁸,Dirnhofer Stephan⁹,Giovanella Luca¹¹⁰,Hayoz Stefanie⁷,Mamot Christoph¹¹,Rambaldi Alessandro⁴¹²,Chauvie Stephane⁵,Zucca Emanuele²⁶¹³^ORCID

Affiliation:

1. Nuclear Medicine and PET/CT Centre Imaging Institute of Southern Switzerland Ente Ospedaliero Cantonale Bellinzona Switzerland

2. Faculty of Biomedical Sciences Institute of Oncology Research Università della Svizzera Italiana Bellinzona Switzerland

3. SIB Swiss Institute of Bioinformatics Lausanne Switzerland

4. Hematology Unit Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy

5. Medical Physics Unit Santa Croce e Carlo Hospital Cuneo Italy

6. Medical Oncology Oncology Institute of Southern Switzerland Ente Ospedaliero Cantonale Bellinzona Switzerland

7. Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center Bern Switzerland

8. Department of Nuclear Medicine Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy

9. Institute of Medical Genetics and Pathology University Hospital Basel University of Basel Switzerland

10. Department of Nuclear Medicine University Hospital Zurich and University of Zurich Zurich Switzerland

11. Division of Oncology Cantonal Hospital Aarau Aarau Switzerland

12. Department of Oncology and Hemato‐Oncology University of Milan Milan Italy

13. Department of Medical Oncology Bern University Hospital and University of Bern Bern Switzerland

Funder

Amgen

Oncosuisse

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2935

Reference50 articles.

1. Diffuse Large B-Cell Lymphoma

2. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

3. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

4. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

5. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis Prediction of Diffuse Large B-Cell Lymphoma in $^{18}$F-FDG PET Images Based on Multi-Deep-Learning Models;IEEE Journal of Biomedical and Health Informatics;2024-07

2. Methodological evaluation of original articles on radiomics and machine learning for outcome prediction based on positron emission tomography (PET);Nuklearmedizin - NuclearMedicine;2023-11-23

3. Pet-radiomics in lymphoma and multiple myeloma: update of current literature;Clinical and Translational Imaging;2023-11-13

4. Prognostic Value of¹⁸F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study;Journal of Nuclear Medicine;2023-11-09

5. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells;Journal of Cancer Research and Clinical Oncology;2023-07-03